PFIZER INC Current Income Tax Expense (Benefit)
PFIZER INC (PFE) reported Current Income Tax Expense (Benefit) of $1.87 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-26
- PFIZER INC current income tax expense (benefit) for fiscal 2025 was $1.87B, a 10.03% decline from fiscal 2024.
- PFIZER INC current income tax expense (benefit) for fiscal 2024 was $2.07B, a 10.91% decline from fiscal 2023.
- PFIZER INC current income tax expense (benefit) for fiscal 2023 was $2.33B.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $1.87B 10-K · filed 2026-02-26 |
| 2024-12-31 | $2.07B 10-K · filed 2026-02-26 |
| 2023-12-31 | $2.33B 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |